Ghosh Abhinandan, Pakhira Bhabani Prasad, Tripathy Adrija, Ghosh Debidas
a Nutrigenomics & Molecular Medicine Laboratory, Department of Bio-Medical Laboratory Science and Management , Vidyasagar University , Midnapore , India.
Pharm Biol. 2017 Dec;55(1):2035-2042. doi: 10.1080/13880209.2017.1357734.
Terminalia chebula Retz (Combretaceae) and Musa balbisiana Colla (Musaceae) have a traditional reputation as a male contraceptive.
To determine the hypo-testicular activity of aqueous extracts of Terminalia chebula (fruit) and Musa balbisiana (seed) separately, and in composite manner at the ratio of 1:1 named as 'Contracept-TM' compared to cyproterone acetate (CPA), for developing a polyherbal contraceptive.
The separate extract of above said plants or 'Contracept-TM' at the dose of 40 mg/100 g body weight of rat/day or CPA at 2 mg/100 g body weight of rat/day was administered for 28 days. Spermiological, androgenic and oxidative stress sensors, LD and ED/100 g body weight values were measured.
Treatment of individual, 'Contracept-TM' or CPA resulted significant decrease in the count of spermatogonia A (36.36-49.09%), pre-leptotene spermatocyte (19.11-55.30%), mid-pachytene spermatocyte (28.65-47.28%) and step 7 spermatid (29.65-51.59%). Activities of testicular Δ, 3β (21.25-48.02%),17β-hydroxysteroid dehydrogenases (29.75-55.08%), catalase (19.06-43.29%) and peroxidase (30.76-62.82%), levels of testosterone (28.15-63.44%), testicular cholesterol (19.61-49.33%), conjugated diene (29.69-84.99%) and thiobarbituric acid reactive substances (41.25-86.73%) were elevated compare to the control. The ED and LD values were 40 mg and 5.8 g (T. chebula), 48 mg and 6.3 g (M. bulbisiana), 40 mg and 6.0 g ('Contracept-TM'), respectively.
The said spermiological and androgenic sensors' levels were decreased significantly by 'Contracept-TM' than its constitutional individual plant extract and it may be comparable to standard anti-testicular drug like CPA. So, it may be concluded that above polyherbal formulation is potent for inducing hypo-testicular activity.
诃子(使君子科)和野芭蕉(芭蕉科)在传统上被认为有男性避孕作用。
分别测定诃子(果实)和野芭蕉(种子)水提取物以及按1:1比例混合的复方提取物(命名为“Contracept-TM”)相对于醋酸环丙孕酮(CPA)的睾丸抑制活性,以研发一种多草药避孕药。
以40毫克/100克大鼠体重/天的剂量给予上述植物的单独提取物或“Contracept-TM”,或以2毫克/100克大鼠体重/天的剂量给予CPA,给药28天。测量精子学、雄激素和氧化应激指标、每100克体重的半数致死量(LD)和有效剂量(ED)值。
单独给予、给予“Contracept-TM”或CPA后,A型精原细胞数量(减少36.36 - 49.09%)、前细线期精母细胞数量(减少19.11 - 55.30%)、中期粗线期精母细胞数量(减少28.65 - 47.28%)和第7步精子细胞数量(减少29.65 - 51.59%)均显著下降。睾丸Δ、3β-羟基类固醇脱氢酶活性(升高21.25 - 48.02%)、17β-羟基类固醇脱氢酶活性(升高29.75 - 55.08%)、过氧化氢酶活性(升高19.06 - 43.29%)和过氧化物酶活性(升高30.76 - 62.82%),睾酮水平(升高28.15 - 63.44%)、睾丸胆固醇水平(升高19.61 - 49.33%)、共轭二烯水平(升高29.69 - 84.99%)和硫代巴比妥酸反应性物质水平(升高41.25 - 86.73%)均高于对照组。“Contracept-TM”、诃子和野芭蕉的ED值分别为40毫克、48毫克和40毫克,LD值分别为6.0克、5.8克和6.3克。
“Contracept-TM”使上述精子学和雄激素指标水平的下降幅度显著大于其组成植物的单独提取物,且可能与标准抗睾丸药物CPA相当。因此,可以得出结论,上述多草药制剂具有显著的睾丸抑制活性。